Posted on

cbd olie voor slapen

Cbd olie voor slapen

★★★★ Prima slaapmiddel!! Absoluut de beste nachtrust die ik in JAREN heb meegemaakt! ! Ik viel snel in slaap, gemakkelijk zonder dat mijn hoofd toeren draaide. Vannacht doorgeslapen en goed uitgerust en alert wakker geworden!! Ik ben meer dan blij met Jennah CBD Olie!

★★★★ GeweldigDit product werkt erg goed. Als je moeite hebt met slapen, is dit wat je nodig hebt. Ik voel me de volgende dag heel kalm en ontspannen als ik wakker word.

Pluk de vruchten van een volledige nachtrust, zoals verbeterde stemming, cognitie en productiviteit.

Soms brengt een slappe nacht ons uit balans. Kom weer op het goede spoor met slechts een paar druppels Jennah CBD Olie.

Krijg je slaap weer op de rails.

Gemaakt met 100% natuurlijke ingrediënten. Zeg vaarwel tegen slaperige ochtenden en synthetische geneesmiddelen.

Jennah Sleep Potion CBD olie kan bijdragen aan een verbeterde slaapkwaliteit. Onze CBD olie is een volledig natuurlijk product en kan jou helpen wanneer je slaapproblemen ondervindt. Een goede nachtrust betekent niet alleen meer energie voor de volgende dag, het draagt ook bij aan je algemene gezondheid.

★★★★Heerlijk geslapen!!Ik heb nog nooit een product zo effectief gebruikt, en ik kan eindelijk een volledige nachtrust krijgen zonder enige verstoring van het wakker worden! Op naar mijn 4e fles!

Een volledig natuurlijk slaapmiddel

CBD olie maakt je geest rustiger waardoor je sneller in slaap valt. Het werkt als een kalmeringsmiddel. De stem in je hoofd zal (letterlijk en figuurlijk) minder overuren maken waardoor je eerder slaapt. Nadat je door de rust sneller in slaap valt, blijf je volgens een dierstudie ook langer slapen.

Cbd olie voor slapen

Kathleen Louden, ELS, of Louden Health Communications provided editorial assistance.

Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature.

The legality of CBD is not clear. Like the issues surrounding the legality of cannabis in general, CBD presents the clinician with a confusing state vs federal legal quandary, and this keeps the issue in question. CBD is legal in the 33 states that have legalized medical or recreational use of marijuana and in 17 other states that have legalized some form of CBD, according to the National Organization for the Reform of Marijuana Laws (NORML).21 But like marijuana, it is still not legal at the federal level. The federal government has announced that it is not focused on this compound in terms of enforcement or interdiction.22 However, CBD is interpreted by the Drug Enforcement Administration, Food and Drug Administration, and Congress to be a Schedule I substance, and therefore it is illegal in all 50 states.23 Pragmatically, CBD is widely available on the Internet, with sales expected to reach $1 billion by 2020. Pending federal legislation to redefine the legal status of cannabis would clarify this complex issue. Canada’s move to legalize cannabis in October 2018 further highlights the need for a speedy resolution to this question.24

Mean anxiety and sleep scores for adults using cannabidiol treatment.


CBD has demonstrated preliminary efficacy for a range of physical and mental health care problems. In the decade before 2012, there were only 9 published studies on the use of cannabinoids for medicinal treatment of pain; since then, 30 articles have been published on this topic, according to a PubMed search conducted in December 2017. Most notable was a study conducted at the University of California, San Diego’s Center for Medicinal Cannabis Research that showed cannabis cigarettes reduced pain by 34% to 40% compared with placebo (17% to 20% decrease in pain).8 In particular, CBD appears to hold benefits for a wide range of neurologic disorders, including decreasing major seizures. A recent large, well-controlled study of pediatric epilepsy documented a beneficial effect of CBD in reducing seizure frequency by more than 50%.9 In addition to endorphin release, the “runner’s high” experience after exercise has been shown to be induced in part by anandamide acting on CB1 receptors, eliciting anxiolytic effects on the body.10 The activity of CBD at 5-HT1A receptors may drive its neuroprotective, antidepressive, and anxiolytic benefits, although the mechanism of action by which CBD decreases anxiety is still unclear.11 CBD was shown to be helpful for decreasing anxiety through a simulated public speaking test at doses of 300 mg to 600 mg in single-dose studies.12–14 Other studies suggest lower doses of 10 mg/kg having a more anxiolytic effect than higher doses of 100 mg/kg in rats.15 A crossover study comparing CBD with nitrazepam found that high-dose CBD at 160 mg increased the duration of sleep.16 Another crossover study showed that plasma cortisol levels decreased more significantly when given oral CBD, 300 to 600 mg, but these patients experienced a sedative effect.17 The higher doses of CBD that studies suggest are therapeutic for anxiety, insomnia, and epilepsy may also increase mental sedation.16 Administration of CBD via different routes and long-term use of 10 mg/d to 400 mg/d did not create a toxic effect on patients. Doses up to 1500 mg/d have been well tolerated in the literature.18 Most of the research done has been in animal models and has shown potential benefit, but clinical data from randomized controlled experiments remain limited.

Often CBD was employed as a method to avoid or to reduce psychiatric medications. The CBD selection and dosing reflected the individual practitioner’s clinical preference. Informed consent was obtained for each patient who was treated and considered for this study. Monthly visits included clinical evaluation and documentation of patients’ anxiety and sleep status using validated measures. CBD was added to care, dropped from care, or refused as per individual patient and practitioner preference. The Western Institutional Review Board, Puyallup, WA, approved this retrospective chart review.

HAM-A = Hamilton Anxiety Rating Scale; PSQI = Pittsburg Sleep Quality Index; SD = standard deviation.


CV Sciences Inc, Las Vegas, NV, provided cannabidiol products for the study. CV Sciences was not involved in the data collection, data interpretation, preparation of the report, or decision to submit the report for publication. No other financial support was provided. The authors would like to express their deep appreciation to the staff and clinicians at Wholeness Center for their professionalism.

These results demonstrated a more sustained response to anxiety than for sleep over time. Patient records displayed a larger decrease in anxiety scores than in sleep scores. The sleep scores demonstrated mild improvement. The anxiety scores decreased within the first month and then remained decreased during the study duration.